Answer
Breastfeeding should be discontinued during capivasertib (Truqap) treatment because it is unknown whether capivasertib or its metabolites enter human milk and a risk to the breastfed child cannot be excluded.
Sources for this answer
- Truqap 160 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 6Document updated
Sources checked